Prior Authorization requirements for Continuous Interstitial Glucose Monitoring

On August 1, 2017, Anthem Blue Cross and Blue Shield prior authorization requirements will change for Continuous Interstitial Glucose Monitoring. Federal and state law, as well as state contract language and Centers for Medicare & Medicaid Services guidelines, including definitions and specific contract provisions/exclusions, take precedence over these prior authorization rules and must be considered first when determining coverage.

Non-compliance with new requirements may result in denied claims. Prior authorization requirements will be added to the codes below:

- A9276: Sensor; invasive (e.g., subcutaneous), disposable, for use with interstitial continuous glucose monitoring system, 1 unit = 1 day supply
- A9277: Transmitter; external, for use with interstitial continuous glucose monitoring system
- A9278: Receiver (monitor); external, for use with interstitial continuous glucose monitoring system

Not all prior authorization requirements are listed here. Detailed prior authorization requirements are available to contracted providers by accessing the “Provider Self-Service Tool” within Availity. Non-contracted providers should contact the health plan.